{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-027935","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.764135+00:00","generated_at":"2026-06-12T02:14:26.361038+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta","bullets":["Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.","Cash, equivalents and marketable securities $286.7M as of June 30, expected to fund ops into 2H 2025.","Exclusive license for CFT8919 (EGFR L858R degrader) with Betta Pharma in Greater China: $10M upfront, $25M equity investment, up to $357M milestones plus royalties.","U.S. IND cleared for CFT8919; Phase 1/2 trials for CFT7455, CFT8634, CFT1946 ongoing; Phase 1 dose escalation data expected 2H 2023.","Appointed Len Reyno as CMO and Mary Christian as SVP Regulatory in July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-027935","json":"https://secwatch.observer/filing/0001628280-23-027935.json","markdown":"https://secwatch.observer/filing/0001628280-23-027935.md","text":"https://secwatch.observer/filing/0001628280-23-027935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/0001628280-23-027935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/cccc-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:14:26.361038+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f9ab1e4202b51d1149e94af22b8d93b96cd5b5e","claim":"C4 Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $2.7 million.","evidence_excerpt":"for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023. SECOND QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. The decrease in revenue was due to a reduction of revenue recognized for research activities under the Biogen and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/0001628280-23-027935-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$2.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}